Nov 17, 2025 • Business Insider
SOMEWHAT-BULLISH
EQS-CMS: Evotec SE: Release of a capital market information
EQS Post-admission Duties announcement: EVOTEC SE / Completion of Share Repurchase Programme / Announcement pursuant to Article 5 ( 1 ) ( b ) , ( 3 ) of Regulation ( EU ) No. 596/2014 in conjunction with Article 2 ( 2 ) and ( 3 ) of Delegated Regulation ( EU ) 2016/1052
Oct 17, 2025 • Zacks Commentary
NEUTRAL
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
Esperion selects ESP-2001 as a preclinical candidate for primary sclerosing cholangitis, a rare liver disease, aiming to begin clinical studies in 2026.
Sep 24, 2025 • Benzinga
SOMEWHAT-BULLISH
Financière de Tubize strengthens its expertise in the biopharma field by appointing 2 new directors
Since the appointment of Bruno Holthof as Chairman of the Board of Directors of the company in April 2025, the company's board has continued to strengthen its expertise in the biopharma field.
Aug 11, 2025 • Business Insider
NEUTRAL
EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: EVOTEC SE Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution Dissemination of a Voting Rights Announcement transmitted by EQS News - a service of EQS Group.
Jul 30, 2025 • Benzinga
SOMEWHAT-BULLISH
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France - Sandoz Group ( OTC:SDZNY )
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar market opportunity over next 10 years[1]